Otonomy Sustained-Release Gels May Solve Ear Med Delivery Problems
This article was originally published in Pharmaceutical Approvals Monthly
Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.
You may also be interested in...
Hearing loss is an arena largely ignored by the biopharmaceutical industry, with most of the innovation coming from med-tech players. That situation is ripe for change as a vanguard of start-ups is attempting to develop novel therapies to treat a variety of hearing disorders, including Ménière's disease and sudden sensorineural hearing loss.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.